• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Arena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program Updates

    2/23/22 4:05:00 PM ET
    $ARNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARNA alert in real time by email

    – Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout

    Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021.

    Key Program & Corporate Updates

    • In December announced that Pfizer Inc. and Arena entered into a definitive agreement under which Pfizer has agreed to acquire Arena
    • In November achieved target enrollment for Study A in the Phase 2/3 CULTIVATE trial for etrasimod in Crohn's disease
    • In November the first participant was randomized in the Phase 2 trial for temanogrel in Raynaud's phenomenon secondary to systemic sclerosis
    • Phase 3 ELEVATE program for etrasimod in ulcerative colitis remains on track for topline data readout in Q1 2022

    Fourth Quarter and Full Year End Financial Updates

    Fourth Quarter 2021 Financial Results

    • Research and development (R&D) expenses for the fourth quarter totaled $110.3 million compared to $100.4 million in the same period in 2020. This increase was primarily driven by our advancing clinical studies, including the etrasimod Phase 3 program, as well as an increase in personnel expenses to support our clinical programs. The R&D non-cash, share-based compensation was $8.4 million in the fourth quarter as compared to $6.5 million in the same period in 2020
    • Selling, general and administrative (SG&A) expenses for the fourth quarter totaled $34.5 million, compared to $34.9 million in the same period in 2020. This decrease was primarily driven by a decline in SG&A non-cash, share-based compensation partially offset by an increase in salary and other personnel expenses. The SG&A non-cash, share-based compensation was $9.8 million in the fourth quarter as compared to $13.5 million in the same period in 2020
    • Net loss for the fourth quarter was $155.6 million compared to a net loss of $122.2 million for the same period in 2020
    • Basic and diluted net loss per share for the fourth quarter was $2.54 compared to basic and diluted net loss per share of $2.10 for the same period in 2020
    • Cash, cash equivalents and marketable securities were $0.7 billion at December 31, 2021 as compared to $1.1 billion at December 31, 2020

    Full Year 2021 Financial Results

    • Revenues totaled $0.1 million
    • Research and development expenses totaled $419.5 million, including $33.5 million related to non-cash share-based compensation
    • Selling, general and administrative expenses totaled $126.2 million, including $36.9 million related to non-cash share-based compensation
    • Net loss was $616.4 million, or $10.14 per share

    We will not be holding a conference call to discuss these financial results or corporate update in light of the proposed transaction with Pfizer announced on December 13, 2021.

    About Arena Pharmaceuticals

    ARENA Pharmaceuticals is a team with a singular purpose – deliver important medicines to patients.

    In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to get medicines to patients, and relentlessly execute until it's done.

    ARENA - Care More. Act Differently.

    Etrasimod and temanogrel are investigational compounds that are not approved for any use in any country.

    Forward-Looking Statements

    Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements may be identified by words such as "on course" and "on track" and include, without limitation, statements about the following: the proposed acquisition of Arena by Pfizer and the timing of data readouts for ongoing trials. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: risks related to the satisfaction or waiver of the conditions to closing the proposed acquisition (including the failure to obtain necessary regulatory approvals) in the anticipated timeframe or at all, including the possibility that the proposed acquisition does not close; clinical trials and other studies may not proceed at the time or in the manner expected or at all; topline data may not accurately reflect the complete results of a particular study or trial; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; the duration and severity of the coronavirus disease (COVID-19) pandemic, including but not limited to the impact on Arena's clinical operations, the operations of Arena's suppliers, partners, collaborators, licensees, and capital markets, which in each case remains uncertain; risks related to unexpected or unfavorable new data; the risk that regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; satisfactory resolution of litigation or other disagreements with others; and risks related to the enforcement of Arena's and third parties' intellectual property rights. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission (SEC), including but not limited to Arena's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, which was filed with the SEC on November 4, 2021. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

    Arena Pharmaceuticals, Inc.

    Condensed Consolidated Statements of Operations

    (In thousands, except per share amounts)

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

     

    2021

     

     

     

    2020

     

     

     

    2021

     

     

     

    2020

     

     

    (unaudited)

     

     

     

     

    Revenues:

     

     

     

     

     

     

     

    Collaboration and other revenue

    $

    54

     

     

    $

    37

     

     

    $

    54

     

     

    $

    57

     

    Royalty revenue

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    262

     

    Total revenues

     

    54

     

     

     

    37

     

     

     

    54

     

     

     

    319

     

    Operating Costs and Expenses:

     

     

     

     

     

     

     

    Research and development

     

    110,341

     

     

     

    100,441

     

     

     

    419,509

     

     

     

    323,740

     

    Acquired in-process research and development

     

    —

     

     

     

    —

     

     

     

    70,000

     

     

     

    —

     

    Selling, general and administrative

     

    34,505

     

     

     

    34,897

     

     

     

    126,206

     

     

     

    103,218

     

    Transaction costs

     

    8,638

     

     

     

    —

     

     

     

    8,638

     

     

     

    —

     

    Total operating costs and expenses

     

    153,484

     

     

     

    135,338

     

     

     

    624,353

     

     

     

    426,958

     

    Loss from operations

     

    (153,430

    )

     

     

    (135,301

    )

     

     

    (624,299

    )

     

     

    (426,639

    )

    Total interest and other income (expense), net

     

    (2,179

    )

     

     

    13,140

     

     

     

    7,866

     

     

     

    21,905

     

    Net loss

    $

    (155,609

    )

     

    $

    (122,161

    )

     

    $

    (616,433

    )

     

    $

    (404,734

    )

     

     

     

     

     

     

     

     

    Net loss per share, basic and diluted:

    $

    (2.54

    )

     

    $

    (2.10

    )

     

    $

    (10.14

    )

     

    $

    (7.39

    )

     

     

     

     

     

     

     

     

    Shares used in calculating net loss per share, basic and diluted:

     

    61,378

     

     

     

    58,288

     

     

     

    60,776

     

     

     

    54,767

     

    Arena Pharmaceuticals, Inc.

    Condensed Consolidated Balance Sheet Data

    (In thousands)

    (Unaudited)

     

     

    December 31,

    2021

     

    December 31,

    2020

     

    (1)

     

    (1)

    Assets

     

     

     

    Cash and cash equivalents

    $

    224,572

     

    $

    219,544

    Prepaid expenses and other current assets

     

    18,996

     

     

    35,266

    Total available-for-sale investments

     

    486,693

     

     

    884,497

    Land, property and equipment, net

     

    19,125

     

     

    22,090

    Other non-current assets

     

    35,319

     

     

    29,323

    Total assets

    $

    784,705

     

    $

    1,190,720

     

     

     

     

    Liabilities and Stockholders' Equity

     

     

     

    Accounts payable and accrued liabilities

     

    61,264

     

     

    53,676

    Total lease financing obligations & other long-term liabilities

     

    50,204

     

     

    56,575

    Total stockholders' equity

     

    673,237

     

     

    1,080,469

    Total liabilities & stockholders' equity

    $

    784,705

     

    $

    1,190,720

    ______________________

    (1) The Condensed Consolidated Balance Sheet Data has been derived from the audited financial statements as of that date.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220223005276/en/

    Get the next $ARNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARNA

    DatePrice TargetRatingAnalyst
    2/9/2022$120.00 → $100.00Buy → Neutral
    HC Wainwright & Co.
    12/21/2021$93.00 → $100.00Overweight → Neutral
    Cantor Fitzgerald
    12/14/2021Market Outperform → Market Perform
    JMP Securities
    12/14/2021$112.00 → $100.00Outperform → Market Perform
    SVB Leerink
    12/14/2021$76.00 → $100.00Outperform → Sector Perform
    RBC Capital
    12/14/2021$98.00 → $100.00Outperform → Neutral
    Credit Suisse
    12/14/2021$100.00Buy → Hold
    Jefferies
    12/13/2021Buy → Hold
    Needham
    More analyst ratings

    $ARNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Arena Pharmaceuticals Inc. (Amendment)

      SC 13G/A - ARENA PHARMACEUTICALS INC (0001080709) (Subject)

      2/11/22 10:07:09 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Arena Pharmaceuticals Inc. (Amendment)

      SC 13G/A - ARENA PHARMACEUTICALS INC (0001080709) (Subject)

      2/9/22 3:24:50 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Arena Pharmaceuticals Inc. (Amendment)

      SC 13G/A - ARENA PHARMACEUTICALS INC (0001080709) (Subject)

      2/4/22 9:26:03 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Arena Pharmaceuticals downgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. downgraded Arena Pharmaceuticals from Buy to Neutral and set a new price target of $100.00 from $120.00 previously

      2/9/22 6:14:57 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arena Pharmaceuticals downgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald downgraded Arena Pharmaceuticals from Overweight to Neutral and set a new price target of $100.00 from $93.00 previously

      12/21/21 5:12:52 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arena Pharmaceuticals downgraded by JMP Securities

      JMP Securities downgraded Arena Pharmaceuticals from Market Outperform to Market Perform

      12/14/21 7:04:00 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ARNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director

      Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion's independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil Barrage who served as the Company's interim Chairman since March 31, 2023. Mr. Barrage will continue to serve as a director on Sensorion's Board. This appointment by the Board of directors is performed b

      4/2/25 1:30:00 AM ET
      $LBPH
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program Updates

      – Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021. Key Program & Corporate Updates In December announced that Pfizer Inc. and Arena entered into a definitive agreement under which Pfizer has agreed to acquire Arena In November achieved target enrollment for Study A in the Phase 2/3 CULTIVATE trial for etrasimod in Crohn's disease In November the first participant was randomized in the Phase 2 trial for temanogrel in Raynaud's phenomenon secondary to systemic sclerosis Phase 3 ELEVATE program

      2/23/22 4:05:00 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the Compensation Committee of its Board of Directors granted to 18 new employees 18,527 inducement restricted stock units ("RSUs"). The inducement RSUs have a grant date and vesting commencement date of February 15, 2022 and were granted as inducements material to the new employees entering employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement RSUs vest over four years, with 25% of the shares vesting on the first designated quarterly vesting date on or following the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in 12 substantially equal quarte

      2/17/22 4:05:00 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Nova Tina Susan disposed of 20,843 shares, closing all direct ownership in the company

      4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)

      3/11/22 4:24:43 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Fetzer Oliver disposed of 9,692 shares, closing all direct ownership in the company

      4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)

      3/11/22 4:24:23 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Gallahue Kieran disposed of 12,911 shares, closing all direct ownership in the company

      4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)

      3/11/22 4:23:59 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARNA
    Financials

    Live finance-specific insights

    See more
    • Arena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program Updates

      – Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021. Key Program & Corporate Updates In December announced that Pfizer Inc. and Arena entered into a definitive agreement under which Pfizer has agreed to acquire Arena In November achieved target enrollment for Study A in the Phase 2/3 CULTIVATE trial for etrasimod in Crohn's disease In November the first participant was randomized in the Phase 2 trial for temanogrel in Raynaud's phenomenon secondary to systemic sclerosis Phase 3 ELEVATE program

      2/23/22 4:05:00 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arena Pharmaceuticals to Release Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update on February 23

      Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will release its fourth quarter and full-year 2021 financial results and provide a corporate update on Wednesday, February 23, 2022, after the close of the U.S. financial markets. About Arena Pharmaceuticals ARENA Pharmaceuticals is a team with a singular purpose – deliver important medicines to patients. In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to get medicines to patients, and relentlessly execute until it's done. ARENA - Care More. Act Differently. Forward-Looking Statements Certain statements in this press relea

      2/9/22 4:05:00 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pfizer to Acquire Arena Pharmaceuticals

      Proposed acquisition offers potentially new, differentiated best-in-class approach to address unmet need for a broader number of patients with immuno-inflammatory diseases Expands innovative pipeline potentially enhancing growth through 2025 and beyond Transaction valued at $100 per Arena share in cash, for a total equity value of approximately $6.7 billion Pfizer to host analyst and investor call at 10am EST today with Pfizer I&I executives Pfizer Inc. (NYSE:PFE) and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapie

      12/13/21 6:45:00 AM ET
      $ARNA
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director

      Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion's independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil Barrage who served as the Company's interim Chairman since March 31, 2023. Mr. Barrage will continue to serve as a director on Sensorion's Board. This appointment by the Board of directors is performed b

      4/2/25 1:30:00 AM ET
      $LBPH
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arena Pharmaceuticals Appoints Doug Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development

      Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced the appointment of Douglas J. Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development, reporting to Amit D. Munshi, President and CEO of Arena. Dr. Manion brings more than 20 years of pharmaceutical industry experience spanning three large companies, including work in all of Arena's therapeutic areas. "We are excited to have Dr. Manion join the Arena team," said Mr. Munshi. "Doug has leadership experience across all aspects of research and development, as well as extensive international experience, which will guide Arena R&D as we continue to grow and progress our portfolio." "I was attracted by the breadt

      7/19/21 8:30:00 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Steven Schoch Elected to Arena Pharmaceuticals Board of Directors

      Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced the appointment of Steven Schoch to the Company's Board of Directors and as Chair of the Audit Committee. Mr. Schoch brings more than 20 years of financial and operational leadership and expertise across a range of areas in biopharmaceuticals, media, and technology, including building and scaling businesses and leading innovation. "We are very pleased to have Mr. Schoch join our Board of Directors," said Garry Neil, M.D., Chair of the Board of Directors of Arena. "Steven brings both financial and strategic operational experience that will be of great benefit as Arena prepares for the next stage of growth." Mr. Schoch currently serv

      6/14/21 8:30:00 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARNA
    SEC Filings

    See more
    • SEC Form 15-12G filed by Arena Pharmaceuticals Inc.

      15-12G - ARENA PHARMACEUTICALS INC (0001080709) (Filer)

      3/21/22 6:03:29 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Arena Pharmaceuticals Inc.

      EFFECT - ARENA PHARMACEUTICALS INC (0001080709) (Filer)

      3/16/22 12:15:11 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Arena Pharmaceuticals Inc.

      EFFECT - ARENA PHARMACEUTICALS INC (0001080709) (Filer)

      3/16/22 12:15:08 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care